Editor in Chief
Continuous, or next-generation, processing remains a hot topic in biomanufacturing because it offers a flexible and efficient approach to making biopharmaceuticals. The number of biomanufacturing steps and holds can be decreased, and operations carried out, with a smaller footprint, equipment, and instrumentation. Experts say the technique can improve product quality and enable real-time release.
BioPlan Associates, which provides strategic, informational, and analytic reports on the biomanufacturing industry, has cited continuous bioprocessing as one of the “top 12 biopharma manufacturing trends.”
In this Next-Gen Bioprocessing Supplement, we take a look at continuous biomanufacturing challenges from a number of areas:
- Fledgling Steps toward Regenerative Medicine Superpowers
- Biomanufacturing Expands its Comfort Zone
- All Roads Lead to Continuous Processing
Also included are sponsored articles on acquiring additional continuous expertise by means of acquisitions, automated dendritic cell production, and how to improve your bioprocessing capabilities. This month, continuous bioprocessing will be discussed at several sessions of the Bioprocessing Summit, as well as at the Bioprocess International Conference in September, both events taking place in Boston.
